Enfusion’s (ENFN) Market Perform Rating Reaffirmed at William Blair

Enfusion (NYSE:ENFN)‘s stock had its “market perform” rating reiterated by investment analysts at William Blair in a research report issued on Monday,Benzinga reports.

A number of other analysts also recently commented on ENFN. Stifel Nicolaus boosted their price objective on Enfusion from $11.00 to $13.00 and gave the stock a “buy” rating in a research note on Wednesday, December 18th. Piper Sandler boosted their price target on shares of Enfusion from $10.00 to $11.50 and gave the stock a “neutral” rating in a research report on Monday, December 23rd. Three equities research analysts have rated the stock with a sell rating, two have assigned a hold rating and two have assigned a buy rating to the stock. Based on data from MarketBeat.com, Enfusion currently has a consensus rating of “Hold” and a consensus price target of $10.25.

Enfusion Stock Performance

Shares of NYSE:ENFN traded up $0.81 during trading on Monday, reaching $10.75. The company had a trading volume of 4,604,483 shares, compared to its average volume of 987,132. Enfusion has a twelve month low of $7.52 and a twelve month high of $11.38. The firm has a market capitalization of $1.38 billion, a PE ratio of 268.82, a price-to-earnings-growth ratio of 3.98 and a beta of 0.95. The firm’s fifty day moving average is $10.11 and its 200 day moving average is $9.20.

Insider Activity at Enfusion

In related news, COO Neal Pawar sold 21,801 shares of the company’s stock in a transaction on Monday, December 2nd. The stock was sold at an average price of $10.03, for a total transaction of $218,664.03. Following the transaction, the chief operating officer now directly owns 1,143,544 shares of the company’s stock, valued at approximately $11,469,746.32. The trade was a 1.87 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Bradley Herring sold 4,134 shares of Enfusion stock in a transaction dated Tuesday, January 7th. The shares were sold at an average price of $10.13, for a total value of $41,877.42. Following the transaction, the chief financial officer now directly owns 266,369 shares in the company, valued at approximately $2,698,317.97. This trade represents a 1.53 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 56,404 shares of company stock worth $580,130 in the last quarter. 36.44% of the stock is owned by company insiders.

Institutional Trading of Enfusion

Institutional investors have recently made changes to their positions in the stock. Arizona State Retirement System purchased a new stake in Enfusion in the 2nd quarter worth approximately $86,000. Harbor Capital Advisors Inc. raised its holdings in shares of Enfusion by 12.4% during the third quarter. Harbor Capital Advisors Inc. now owns 11,887 shares of the company’s stock worth $113,000 after acquiring an additional 1,315 shares in the last quarter. Belvedere Trading LLC acquired a new stake in Enfusion during the third quarter valued at $114,000. Paloma Partners Management Co purchased a new position in Enfusion in the third quarter valued at about $157,000. Finally, The Manufacturers Life Insurance Company increased its position in Enfusion by 27.7% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 19,562 shares of the company’s stock worth $167,000 after purchasing an additional 4,239 shares during the last quarter. 81.05% of the stock is currently owned by institutional investors and hedge funds.

Enfusion Company Profile

Enfusion, Inc provides software-as-a-service solutions for investment management industry in the United States, Europe, the Middle East, Africa, and the Asia Pacific. The company provides Portfolio Management System, which generates a real-time investment book of record that consists of valuation and risk tools, which allows users to analyze aggregated or decomposed portfolio data for chief investment officers (CIOs) and portfolio managers; and Order and Execution Management System that enables portfolio managers, traders, compliance teams, and analysts to electronically communicate trade orders for a variety of asset classes, manage trade orders, and systemically enforce trading regulations and internal guidelines.